Rheumatoid arthritis patients whose disease flares unpredictably or resists treatment are the focus of a new phase of research by a consortium of UK universities. This matters because while scientists understand how rheumatoid arthritis begins, they know far less about why some patients never achieve remission, why others experience sudden flares after periods of stability, and why certain people do not respond to any available therapy. The research will dissect what happens inside the joint tissue—the synovium and surrounding lymphoid tissues—during these different disease states, using advanced molecular and cellular techniques to map the biological processes driving each phase. If successful, the work could identify new targets for drugs that prevent flares or treat refractory disease, rather than only managing early-stage inflammation. It may also reveal why some forms of inflammatory arthritis, such as psoriatic arthritis, behave differently from rheumatoid arthritis, potentially leading to more precise treatments for each condition. The project is primarily discovery-driven fundamental science, but its focus on patient-reported problems—flare and drug resistance—means any biological insights are likely to feed directly into clinical trials and eventually change how doctors manage long-term arthritis care.
View original technical description
The Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE) comprises a partnership between the Universities of Birmingham, Glasgow and Newcastle. Our renewal will integrate the Kennedy Institute for Rheumatology, University of Oxford. Evidenced by publications, research income, training portfolio, and influence in the RA pathogenesis field, RACE has firmly established itself as a world-leading collaboration: critically, RACE has delivered added value by increasing collaborative outputs, but also by enhancing the productivity of each participant university. Thus far, we have explored the biology of RA across disease phases, especially the immunological events leading to breach of tolerance, early synovitis and progression to chronicity. Our second phase (RACE2) will further develop these themes but, informed by patient feedback, will additionally focus on established RA, in particular remission, flare and refractory disease. Across two themes, our programme of cross-cutting “research clusters” will include discovery molecular and cellular science, translational and experimental medicine, and clinical trials. RACE2 will focus primarily on “tissue pathogenesis” of RA in the synovium and wider lymphoid tissues, deconstructing disease pathology using optimal contemporary methodologies. Thus, we have created a fourth ‘cluster’ namely that of underpinning technologies that is truly state-of-the-art in empowering molecular genomics through cellular analyses to experimental medicine, all supported by bioinformatic and systems modelling expertise. RACE2 will deliver an expanded four-centre PhD training programme and maintain exemplary opportunities for post-doctoral scientific training within an innovative, team-based discovery-lead culture. Finally, RACE2 will extend our investigations into the parallel but discrete pathogenesis of seronegative arthropathies, including psoriatic arthritis, as critical comparators to RA. Our vision at the end of this renewal is to broker a national axis with harmonised purpose and strategy for the investigation of inflammatory arthritis, achieved by a knowledge-driven, inclusive approach within and outwith the Centre.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know